MASTER THE COMPLEXITIES OF PHARMACY AND DISTRIBUTION MODELS TO ACCELERATE PATIENT ACCESS

December 12-14, 2022 | USA

MASTER THE
Optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement
Register Now

Spotlight

In recent years, FDA has made great advances in the review of new drugs. From 2012 to 2015, FDA approved a record number of marketing applications for novel drugs, averaging 38 approved products per year. In 2016, FDA approved only 22 novel drugs but the percentage of applications leveraging an expedited program was at its highest.


OTHER UPCOMING CONFERENCES

16th World Drug Delivery Summit

October 28-29, 2022 | Canada

Conference Series LLC Ltd with great pride and honour announcing its "16th World Drug Delivery Summit " (Drug Delivery 2022), which is going to be held during October 28-29, 2022 Vancouver, Canada and invite all the participants all around the world. The theme of the conference is “Advancement in the Technologies used in Drug Delivery”.
Register Now

iPharma Expo 2022

October 20-21, 2022 | USA

After a series of many successful pharma and medical conferences and expos for the past many years, we are happy to announce the International Pharmaceutical Business Expo, iPharma Expo 2022 at Boston, USA during October 20- 21, 2022.
Register Now

2022 ISPE Annual Meeting & Expo

October 30-November 2, 2022 | USA

The 2022 ISPE Annual Meeting & Expo will usher in a revitalized focus on excellence, modernization, and harmonization in pharmaceutical science and manufacturing across the globe, offering pharma professionals the opportunity to engage in industry-critical conversations.
Register Now

18th BIOSIMILAR MEDICINES CONFERENCE

October 6-7, 2022 | USA

During this in-person event, speakers and panellists will explore how to turn the Pharmaceutical Strategy aim to ensure better access and affordability into concrete biosimilar medicine policy measures.
Register Now

Spotlight

In recent years, FDA has made great advances in the review of new drugs. From 2012 to 2015, FDA approved a record number of marketing applications for novel drugs, averaging 38 approved products per year. In 2016, FDA approved only 22 novel drugs but the percentage of applications leveraging an expedited program was at its highest.

resources